• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增殖性肿瘤的流行病学:我们了解什么?

Epidemiology of MPN: what do we know?

作者信息

Anderson L A, McMullin M F

机构信息

Centre for Public Health, Queen's University Belfast, Grosvenor Road, Belfast, BT12 6BJ, Northern Ireland,

出版信息

Curr Hematol Malig Rep. 2014 Dec;9(4):340-9. doi: 10.1007/s11899-014-0228-z.

DOI:10.1007/s11899-014-0228-z
PMID:25129052
Abstract

The myeloproliferative neoplasms, are characterised by overproduction of myeloid cells. Chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, myelofibrosis and the very rare disorders chronic neutrophilic leukaemia, chronic eosinophilic leukaemia not otherwise specified and mastocytosis are all included in the group. Incidence and prevalence rates reported in the worldwide literature are presented in this review. Survival data on each condition is described. Information on the aetiology of the disorders is discussed including body mass index, diet, smoking and alcohol, allergies, associated medical conditions, occupation and environmental exposures with focus on recent new studies. The aetiology of the myeloproliferative neoplasms remains unknown, and this review of the current state of knowledge highlights the need for further comprehensive research.

摘要

骨髓增殖性肿瘤的特征是髓系细胞过度生成。慢性髓性白血病、真性红细胞增多症、原发性血小板增多症、骨髓纤维化以及非常罕见的疾病慢性中性粒细胞白血病、未另行指定的慢性嗜酸性粒细胞白血病和肥大细胞增多症均包含在该组中。本综述介绍了全球文献报道的发病率和患病率。描述了每种疾病的生存数据。讨论了有关这些疾病病因的信息,包括体重指数、饮食、吸烟和饮酒、过敏、相关疾病、职业和环境暴露,并重点关注最近的新研究。骨髓增殖性肿瘤的病因仍然不明,对当前知识状态的这一综述强调了进一步进行全面研究的必要性。

相似文献

1
Epidemiology of MPN: what do we know?骨髓增殖性肿瘤的流行病学:我们了解什么?
Curr Hematol Malig Rep. 2014 Dec;9(4):340-9. doi: 10.1007/s11899-014-0228-z.
2
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.2001 - 2012年美国骨髓增殖性肿瘤和骨髓增生异常/骨髓增殖性肿瘤的发病率及患者生存率
Br J Haematol. 2016 Aug;174(3):382-96. doi: 10.1111/bjh.14061. Epub 2016 Apr 7.
3
[Epidemiologic features of Philadelphia-negative chronic myeloproliferative disorders in Szabolcs-Szatmár-Bereg county, Hungary. Analysis of data of a 33-year period].[匈牙利绍博尔奇-萨特马尔-贝赖格州费城阴性慢性骨髓增殖性疾病的流行病学特征。33年数据的分析]
Orv Hetil. 2017 Apr;158(15):572-578. doi: 10.1556/650.2017.30701.
4
Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.骨髓增殖性疾病的流行病学:原发性血小板增多症、真性红细胞增多症和原发性骨髓纤维化
Pathol Biol (Paris). 2001 Mar;49(2):164-6. doi: 10.1016/s0369-8114(00)00023-7.
5
Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.骨髓增殖性肿瘤继发布加综合征的肝移植患者的长期预后
Liver Int. 2015 Aug;35(8):2042-9. doi: 10.1111/liv.12816. Epub 2015 Mar 31.
6
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.骨髓增殖性肿瘤:组织学和遗传学的当代诊断。
Nat Rev Clin Oncol. 2009 Nov;6(11):627-37. doi: 10.1038/nrclinonc.2009.149. Epub 2009 Oct 6.
7
Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.骨髓增殖性肿瘤:挪威的发病率、患病率及生存率趋势
Eur J Haematol. 2017 Jan;98(1):85-93. doi: 10.1111/ejh.12788. Epub 2016 Sep 4.
8
Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986.1980年至1986年间科多尔省的骨髓增殖性疾病
Nouv Rev Fr Hematol (1978). 1989;31(5):375-8.
9
The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.2010 年至 2017 年新西兰骨髓增殖性肿瘤的流行病学:来自新西兰癌症登记处的见解。
Curr Oncol. 2021 Apr 18;28(2):1544-1557. doi: 10.3390/curroncol28020146.
10
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.经典骨髓增殖性肿瘤的流行病学:一幅广阔而复杂图谱的四个角落。
Blood Rev. 2020 Jul;42:100706. doi: 10.1016/j.blre.2020.100706. Epub 2020 May 22.

引用本文的文献

1
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值作为 BCR-ABL 阴性骨髓增殖性肿瘤的新型预后生物标志物。
Ann Hematol. 2024 Nov;103(11):4545-4556. doi: 10.1007/s00277-024-06023-0. Epub 2024 Sep 27.
2
Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores.真实世界电子病历数据可识别骨髓纤维化的风险因素,并可用于验证既定的预后评分。
Cancers (Basel). 2024 Apr 5;16(7):1416. doi: 10.3390/cancers16071416.
3
Blood sampling patterns in primary care change several years before a cancer diagnosis.

本文引用的文献

1
How common are myeloproliferative neoplasms? A systematic review and meta-analysis.骨髓增殖性肿瘤的发病率有多高?一项系统评价和荟萃分析。
Am J Hematol. 2014 Jun;89(6):581-7. doi: 10.1002/ajh.23690.
2
Epidemiology of systemic mastocytosis in Denmark.丹麦系统性肥大细胞增多症的流行病学。
Br J Haematol. 2014 Aug;166(4):521-8. doi: 10.1111/bjh.12916. Epub 2014 Apr 25.
3
Magnetic fields and brain tumour risks in UK electricity supply workers.英国电力供应行业工人的磁场暴露与患脑肿瘤风险
在癌症诊断前数年,初级保健中的血液采样模式会发生变化。
Acta Oncol. 2024 Feb 13;63:17-22. doi: 10.2340/1651-226X.2024.28559.
4
Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke.年轻脑卒中患者中不确定潜能克隆性造血的流行情况及其治疗意义。
Stroke. 2023 Apr;54(4):938-946. doi: 10.1161/STROKEAHA.122.041416. Epub 2023 Feb 15.
5
Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of myelofibrosis.表达谱分析确定特定的干扰素刺激特征作为骨髓纤维化的潜在诊断和预测指标。
Front Genet. 2022 Aug 18;13:927018. doi: 10.3389/fgene.2022.927018. eCollection 2022.
6
The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.骨髓增殖性肿瘤的分类:基本原理、历史背景及未来展望,重点关注不可分类的病例
Cancers (Basel). 2021 Nov 12;13(22):5666. doi: 10.3390/cancers13225666.
7
NK Cells in Myeloproliferative Neoplasms (MPN).骨髓增殖性肿瘤(MPN)中的自然杀伤细胞
Cancers (Basel). 2021 Aug 31;13(17):4400. doi: 10.3390/cancers13174400.
8
Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.与端粒长度和骨髓增生性肿瘤发病风险相关的遗传多态性。
Blood Cancer J. 2020 Sep 1;10(8):89. doi: 10.1038/s41408-020-00356-5.
9
Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment.骨髓增殖性肿瘤的数学建模为个性化治疗提供理解和决策支持。
Cancers (Basel). 2020 Jul 30;12(8):2119. doi: 10.3390/cancers12082119.
10
Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.费城染色体阴性慢性骨髓增殖性肿瘤的癌症免疫疗法
Cancers (Basel). 2020 Jul 2;12(7):1763. doi: 10.3390/cancers12071763.
Occup Med (Lond). 2014 Apr;64(3):157-65. doi: 10.1093/occmed/kqu003. Epub 2014 Feb 21.
4
Risk of myeloproliferative disease and chronic myeloid leukaemia following exposure to low-level benzene in a nested case-control study of petroleum workers.石油工人巢式病例对照研究中低水平苯暴露与骨髓增生性疾病和慢性髓性白血病发病风险。
Occup Environ Med. 2014 Apr;71(4):266-74. doi: 10.1136/oemed-2013-101664. Epub 2014 Feb 14.
5
Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.合并症和骨髓纤维化程度对原发性骨髓纤维化患者生存预后的影响。
Med Oncol. 2014 Mar;31(3):869. doi: 10.1007/s12032-014-0869-8. Epub 2014 Feb 6.
6
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.CALR 和 ASXL1 基因突变在原发性骨髓纤维化中的分子预后:一项 570 例患者的国际研究。
Leukemia. 2014 Jul;28(7):1494-500. doi: 10.1038/leu.2014.57. Epub 2014 Feb 5.
7
Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients.特发性血小板增多症中的血栓形成与生存:一项 1144 例患者的区域性研究。
Am J Hematol. 2014 May;89(5):542-6. doi: 10.1002/ajh.23685. Epub 2014 Feb 21.
8
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.ASXL1 突变而非 TET2 突变对伴有克隆性血液非肥大细胞疾病的系统性肥大细胞增多症患者的总生存产生不利影响。
PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.
9
Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.口服治疗新时代慢性髓性白血病患者生存的决定因素:来自英国基于人群的患者队列的研究结果
BMJ Open. 2014 Jan 15;4(1):e004266. doi: 10.1136/bmjopen-2013-004266.
10
CALR mutation studies in chronic neutrophilic leukemia.慢性嗜中性粒细胞白血病中的CALR突变研究
Am J Hematol. 2014 Apr;89(4):450. doi: 10.1002/ajh.23665. Epub 2014 Mar 7.